Screener
BioMarin Pharmaceuticals BMRN Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Other long-term liabilities | 209,815 | 150,816 |
| Total liabilities | 5,401,750 | 1,507,023 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively | 194 | 192 |
| Additional paid-in capital | 6,037,019 | 5,956,582 |
| Company common stock held by the Nonqualified Deferred Compensation Plan | (11,233) | (10,508) |
| Accumulated other comprehensive loss | (8,783) | (13,473) |
| Retained earnings | 304,495 | 154,206 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's common stock?
- BioMarin Pharmaceuticals (BMRN) reported common stock of 500M in Q2 2026.
- How has BioMarin Pharmaceuticals's common stock changed year-over-year?
- BioMarin Pharmaceuticals's common stock decreased by 0.0% year-over-year, from 500M to 500M.
- What is the long-term trend for BioMarin Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's common stock has grown at a 387.3% compound annual growth rate (CAGR), from 182K to 500M.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about BioMarin Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude